QUIBIM, a Spanish startup that develops basic AI models for medical images that spans oncology, immunology, neurology, and metabolic disorders, has raised $ 50 million in the series A -round funding.
Cash injections range from drug discovery to clinical trials, as AI deeply into health care.
Quibim is established to enhance diagnostic accuracy and disease detection from visual data procured from X -rays, CT scans, and MRI. The company's flagship product, QP Pro State, is designed to improve prostate cancer detection using separate products for the brain, liver, breast, and lungs.
Apart from that, QUIBIM also provides QP insights for processing multi -woxed data (that is, various types of biological data), such as clinical trials and related research.
QUIBIM says that its long -term plan is to create a digital twin throughout the human, and provide a “dynamic model” that helps the medical community understand the human body better. Everything starts with the “level of organs and lesions”, as the QP Prostate indicates.
Quibim: QP-InsightSimage Credit: Quibim
Plan to grow in the United States
Valencia -based QUIBIM has been raising approximately $ 70 million since its establishment, and the company plans to double its US expansion plan. In fact, Quibim received the FDA 510 (K) clearance in 2023 and sold QP forecast products. He also hired the first highest medical manager in the United States.
At the time of writing, Quibim says that there are 170 installations around the world, along with partners such as Stanford University and Harvard integrated healthcare system Mass General Brigham. Apart from that, Philips had previously announced a plan to integrate the QUIBIM AI model into a scanner.
The QUIBIM series A -rounds are led by Spain's Venture Capital Company and Private Equity Firm Buenavista, Amadeus Capital Partners, APEX and iPod. Many organizations and individual investors including the co -author of the iPhone I have obtained participation from.
“Kibim's mission is to change imaging into a precise healthy catalyst,” said Quibim's CEO and co-founder, Angel Alberich-Bayyarri. “The global expansion to the United States is an important milestone to cooperate with pharmaceutical leaders and medical providers, revolutionize the diagnosis and release the power of imaging to improve patients' transformation.”